<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
    <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
    <journal-title-group>
      <journal-title>Scientific Reports</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2045-2322</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9734560</article-id>
    <article-id pub-id-type="publisher-id">25530</article-id>
    <article-id pub-id-type="doi">10.1038/s41598-022-25530-6</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ApInAPDB: a database of apoptosis-inducing anticancer peptides</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Faraji</surname>
          <given-names>Naser</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Arab</surname>
          <given-names>Seyed Shahriar</given-names>
        </name>
        <address>
          <email>sh.arab@modares.ac.ir</email>
        </address>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Doustmohammadi</surname>
          <given-names>Alireza</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Daly</surname>
          <given-names>Norelle L.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Khosroushahi</surname>
          <given-names>Ahmad Yari</given-names>
        </name>
        <address>
          <email>yarikhosroushahia@tbzmed.ac.ir</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution>Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, </institution><institution>Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution>Drug Applied Research Center, </institution><institution>Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412266.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1781 3962</institution-id><institution>Department of Biophysics, Faculty of Biological Sciences, </institution><institution>Tarbiat Modares University, </institution></institution-wrap>Tehran, Iran </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.1011.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0474 1797</institution-id><institution>Centre for Molecular Therapeutics, </institution><institution>Australian Institute of Tropical Health and Medicine, James Cook University, </institution></institution-wrap>Cairns, QLD Australia </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>9</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>9</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>21341</elocation-id>
    <history>
      <date date-type="received">
        <day>16</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>30</day>
        <month>11</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">ApInAPDB (Apoptosis-Inducing Anticancer Peptides Database) consists of 818 apoptosis-inducing anticancer peptides which are manually collected from research articles. The database provides scholars with peptide related information such as function, binding target and affinity, IC50 and etc. In addition, GRAVY (grand average of hydropathy), net charge at pH 7, hydrophobicity and other physicochemical properties are calculated and presented. Another category of information are structural information includes 3D modeling, secondary structure prediction and descriptors for QSAR (quantitative structure–activity relationship) modeling. In order to facilitate the browsing process, three types of user-friendly searching tools are provided: top categories browser, simple search and advanced search. Overall ApInAPDB as the first database presenting apoptosis-inducing anticancer peptides can be useful in the field of peptide design and especially cancer therapy. Researchers can freely access the database at <ext-link ext-link-type="uri" xlink:href="http://bioinf.modares.ac.ir/software/ApInAPDB/">http://bioinf.modares.ac.ir/software/ApInAPDB/</ext-link>.</p>
    </abstract>
    <kwd-group kwd-group-type="npg-subject">
      <title>Subject terms</title>
      <kwd>Cancer</kwd>
      <kwd>Computational biology and bioinformatics</kwd>
      <kwd>Drug discovery</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004366</institution-id>
            <institution>Tabriz University of Medical Sciences</institution>
          </institution-wrap>
        </funding-source>
        <award-id>65618</award-id>
        <award-id>65618</award-id>
        <principal-award-recipient>
          <name>
            <surname>Faraji</surname>
            <given-names>Naser</given-names>
          </name>
          <name>
            <surname>Khosroushahi</surname>
            <given-names>Ahmad Yari</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>(Bio-Mathematics with computational approach) of Tarbiat Modares University</institution>
        </funding-source>
        <award-id>IG-39706</award-id>
        <award-id>IG-39706</award-id>
        <principal-award-recipient>
          <name>
            <surname>Arab</surname>
            <given-names>Seyed Shahriar</given-names>
          </name>
          <name>
            <surname>Doustmohammadi</surname>
            <given-names>Alireza</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par2">Cancer, one of the most serious public health problems on a global scale<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, has significant treatment challenges including multidrug resistance and a lack of tumor-specific therapies with minimal side effects<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Peptide-based therapy is a new strategy in cancer treatment<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Anticancer peptides (ACPs) possess some advantages like short sequence (less than 50 amino acids)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, easy synthesis and modification, cost-effectiveness, biocompatibility, specific targeting, and low intrinsic toxicity<sup><xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref></sup> that makes them promising as anticancer therapeutics<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. ACPs have been categorized based on structure and activity. The structural categories include α-helical, β-sheet, random coil, and cyclic peptides. Since α-helical and β-sheet conformations have their advantages and disadvantages in anticancer peptide performance<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, secondary structure prediction plays an important role in anticancer peptide design. Although the anticancer mechanism of ACPs is not thoroughly understood<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, they are generally divided into four groups based on their activities I) cell membrane disruption; II) apoptosis-inducing; III) anti-angiogenesis peptides, and IV) immune regulation<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Among these bioactivities, the apoptosis pathway is considered the most successful treatment in non-surgical cancer therapies because it induces minimal inflammation and damage into the treated tissues<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>, highlighting the potential of apoptosis-inducing peptides<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. The BCL-2 family is the main proteins that regulate the intrinsic apoptosis pathway while TNFR, FAS (CD95), and DR3/WSL are involved in extrinsic apoptosis<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Peptide-based cancer therapy can target both apoptosis pathways<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. However, the origin of apoptosis-inducing anticancer peptides is not confined to analogues of the BCL-2 family. Numerous peptides such as human second mitochondria-derived activator of caspase (SMAC) peptides, venom-derived peptides and also antimicrobial peptides have been discovered with apoptosis induction effects on cancerous cells<sup><xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref></sup>. Despite significant interest in peptide-based cancer therapy, there are limited anticancer peptide databases like CancerPPD<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> (anticancer peptides and proteins database), and to our knowledge, no database specifically includes apoptosis-inducing peptides. Here we have established ApInAPDB (Apoptosis-Inducing Anticancer Peptides Database) as a comprehensive database that is dedicated to apoptosis-inducing peptides and their analogues regardless of their degree of effectiveness. The information available in the database, taken from the literature, includes binding target, function, and their effectiveness reported as IC50, binding affinity or spot array. This database also presents additional information such as amino acid composition, hydrophobicity, charge and also prediction of secondary structure using different algorithms. All properties calculated for each peptide and also different algorithms used for structural prediction will be discussed in the database information section. The overall ApInAPDB structure with its features is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. This database has the potential to aid in the development and design of novel apoptosis-inducing peptides.<fig id="Fig1"><label>Figure 1</label><caption><p>Overall structure and features of ApInAPDB.</p></caption><graphic xlink:href="41598_2022_25530_Fig1_HTML" id="MO1"/></fig></p>
  </sec>
  <sec id="Sec2">
    <title>Results</title>
    <p id="Par3">The ApInAPDB interface (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) has been designed for searching and browsing the database conveniently. Instructions on how to search and browse in this user-friendly interface are given below.
<fig id="Fig2"><label>Figure 2</label><caption><p>Schematic representation of ApInAPDB interface.</p></caption><graphic xlink:href="41598_2022_25530_Fig2_HTML" id="MO2"/></fig></p>
    <sec id="Sec3">
      <title>Searching tool</title>
      <sec id="Sec4">
        <title>Simple search</title>
        <p id="Par4">Through a simple search box, keywords can be searched on peptide name, cell line, whole/partial peptide sequence or binding target. Here the keyword search for each field is done separately.</p>
      </sec>
      <sec id="Sec5">
        <title>Advanced search</title>
        <p id="Par5">This search allows the users to select more than one field at a time. For some fields such as charge of peptide, a range can be defined and for some fields such as cell line, more than one option can be selected. Consequently, users can find peptides with multiple desired properties. Among these properties, secondary structure is more complex and users can confine the searching via parameters including Min/Max content of Helix, Extended, Turn and random coil peptides. An example of result page is displayed in Fig. <xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Figure 3</label><caption><p>An example of result page: Original information (left), secondary structures prediction (middle), physicochemical properties (right top) and descriptors for QSAR modeling (right down).</p></caption><graphic xlink:href="41598_2022_25530_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Top categories browser</title>
      <p id="Par6">The top categories browser was developed to find information based on five major categories including length of peptide sequence, peptide charge, source, binding target and finally secondary structure. Through this, users can browse the database more easily. As length, charge and secondary structure play crucial roles in peptide efficiency and knowing their source and binding target is critical information, users can browse and compare the different peptides based on these categories and gain more insight into peptide design. A schematic representation of distribution of apoptosis-inducing Anticancer Peptides based on length, binding target, source and charge is shown in Fig. <xref rid="Fig4" ref-type="fig">4</xref>.<fig id="Fig4"><label>Figure 4</label><caption><p>Representation of distribution based on (<bold>a</bold>) binding target, (<bold>b</bold>) length, (<bold>c</bold>) source and (<bold>d</bold>) charge in ApInAPDB.</p></caption><graphic xlink:href="41598_2022_25530_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec7">
      <title>Data statistics</title>
      <p id="Par7">In total 818 peptides and analogues are listed in ApInAPDB; 787 linear and 31 cyclic peptides. The database consists of 797 peptides containing L-amino acids, one containing D-amino acids and 20 having both L and D amino acids. 224 peptides have been evaluated on different cell lines including HeLa, MCF-7, Jurkat, MDA-MB-435, HepG2, and for 119 peptides IC50 values are reported. The cell line and IC50 of each peptide are stored in the database. Binding affinity of 628 peptides are provided: for 110 peptides ki or kd and for 518 peptides, SPOT array substitution analysis binding to Mcl-1 (100 nM) and Bcl-xl (100 nM) are reported and compiled in the database. The secondary structures of 765 peptides were predicted using different algorithms available on Center for Information Biology (CIB) facilities. Cyclic peptides, D-peptides and those containing modified amino acids were not included in this prediction due to the limitation algorithms. Also, using a de novo approach with the PEP-FOLD3 server, peptide structures were predicted. Some peptides were not considered in this modeling because of limitations with PEP-FOLD3 including peptide size (between 5 and 50 residues) and amino acid types. In total, the structures of 765 peptides were predicted and then compiled in the database. In addition, descriptors of 777 peptides were calculated using Biotriangle web server for QSAR (quantitative structure–activity relationship) modeling development. Other peptides were excluded due to amino acid type's limitation of the web server.</p>
    </sec>
  </sec>
  <sec id="Sec8">
    <title>Discussion</title>
    <p id="Par8">Peptides possess considerable potential in cancer therapy due to their target specificity. Several peptides have recently been approved for cancer treatment, including leuprolide, Buserelin, Gonadorelin, Cetrorelix, Abarelix, Degarelix, and Octreotide. In addition, several anticancer peptides are in or about to enter clinical trials, including BT1718, DPT-C9h, p28<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Since deregulation of apoptosis is a feature of many cancers, drugs including peptides which induce normal apoptosis pathway are potential candidates for treating cancers efficiently<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, Thus, there is great interest in designing apoptosis-inducing peptides for cancer therapy, and abundance of literature is available in this area<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. There are several databases which collected peptides and proteins used in cancer therapy researches like CancerPPD<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, TumorHope<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> (tumor homing peptides database), dbPepNeo<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> (human tumor neoantigen peptides database) and ApoCanD<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> (human apoptotic proteins database on cancer) but there is not any database which present specifically apoptosis-inducing peptides thus this study aimed to develop ApInAPDB to cover this gap. ApInAPDB attempts to present information for researchers interested in studying and developing apoptosis inducing peptides in order to: (1) find the most efficient peptide, (2) determine if designed peptides are novel, (3) perform docking, molecular dynamic simulation and screening for peptides with known binding target reported for each peptide (4) develop QSAR models for those analogues with the same lead peptide/ protein using calculated descriptor files (5) design apoptosis-inducing peptides focusing on the secondary structure prediction, (6) find comprehensive physicochemical properties as well as original information, and (7) browse database with a user-friendly searching tool.</p>
  </sec>
  <sec id="Sec9">
    <title>Methods</title>
    <sec id="Sec10">
      <title>Data collection</title>
      <p id="Par9">This study aimed to establish a database including anticancer peptides with apoptosis activity regardless of their degree of effectiveness. To cover this aim, collecting and investigating a great number of research articles and available databases such as DRAMP<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> (antimicrobial peptides database) are required. The most relevant research articles were manually gathered from Scopus, Google Scholar, and PubMed using keywords such as 'apoptotic peptides', 'BCL2 family peptides', 'apoptosis-inducing peptides', 'BH3 mimicking peptides', 'anticancer peptides' and their combination. The collected articles were carefully studied by the authors to select those that reported the apoptosis-inducing property for their investigated peptide. Accordingly, the irrelevant articles were excluded and relevant articles that experimentally recommended the apoptosis-inducing peptides or innately apoptotic peptides like Bim (BCL-2 interacting mediator of cell death) analogues were included in the database. Totally 818 apoptosis-inducing peptides were presented in the ApInAPDB. Out of them, 783 peptides were collected from research articles and 35 peptides were collected from DRAMP database.</p>
    </sec>
    <sec id="Sec11">
      <title>ApInAPDB web interface</title>
      <p id="Par10">Using MySQL (version 8.0), the collected data is managed. There are two parts to the development of the web interface: front-end development (what the user sees when he encounters the website) and back-end development (connecting the website to the database and querying it to get results). The front end of the website was developed using HTML5, CSS3, PHP (version 7.4), JavaScript ES6, and Jquery (version 3.5.1). The back-end of the website is also developed using PHP. In addition, Google Charts was used to plot all of the charts.</p>
    </sec>
    <sec id="Sec12">
      <title>Database information</title>
      <p id="Par11">Three categories of information are stored in ApInAPDB as original, physicochemical properties and structural information. The original information gathered from research articles includes peptides name, source, sequence, sequence length, N-terminal modification, C-terminal modification, binding target, L/D/Mix, presence of non-natural amino acid, linear/cyclic, function, journal name, publication year, DOI, authors, the title of the paper, cell lines, IC50 of peptide and binding affinity. The next category is physicochemical properties which are derived from the original information. Since peptide properties such as isoelectric point, molecular weight, net charge, etc., play an important role in cancer cell proliferation inhibition or eradication<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, they are reported in the database including molecular weight (g/mol), amino acid composition, hydrophobic/acidic/neutral/basic amino acid percentage, net charge at pH 7, isoelectric point, hydrophobicity at pH 2.0, hydrophobicity at pH 6.8 and charge using biosyn peptide property calculator v3.1 online tool (<ext-link ext-link-type="uri" xlink:href="https://www.biosyn.com">https://www.biosyn.com</ext-link>). Also, GRAVY (grand average of hydropathy) of each peptide is reported in the database using novoprolabs peptide property calculator online tool (<ext-link ext-link-type="uri" xlink:href="https://www.novoprolabs.com/tools/calc_peptide_property">https://www.novoprolabs.com/tools/calc_peptide_property</ext-link>). The third and last category is structural information including descriptors for QSAR modeling, secondary structure prediction and 3D modeling. To help scientists in QSAR modeling development, 1559 descriptors are calculated for each peptide using BioProt available in Biotriangle web server (<ext-link ext-link-type="uri" xlink:href="http://biotriangle.scbdd.com/protein/index/">http://biotriangle.scbdd.com/protein/index/</ext-link>)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> and presented as downloadable CSV file format (The exemplary hyperlink belongs to ZXR-1 peptide). As peptide secondary structure plays an important role in binding to the target, secondary structure prediction is reported in ApInAPDB database using GOR (Garnier, Osguthorpe and Robson method), Neural Network and Chou-Fasman algorithms (<ext-link ext-link-type="uri" xlink:href="http://cib.cf.ocha.ac.jp/bitool/MIX/">http://cib.cf.ocha.ac.jp/bitool/MIX/</ext-link>) (ver. 1.1) available on Center for Information Biology (CIB) created by Ochanomizu University. Furthermore, CIB provides users with the facility to make a consensus on the secondary structure prediction according to the three aforementioned algorithms. Using this ability, a consentaneous result is reported for each peptide. Additionally, using PEP-FOLD3 server (<ext-link ext-link-type="uri" xlink:href="https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD3/">https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD3/</ext-link>)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> both Local Structure prediction profile and downloadable PDB structure file are available (The exemplary hyperlink belongs to ZXR-1 peptide).</p>
    </sec>
  </sec>
  <sec id="Sec13">
    <title>Conclusions</title>
    <p id="Par12">Nowadays, apoptosis-inducing peptides play an important role in cancer therapy and they attract the attention of researchers in the field of peptide design and synthesis. This fact calls for a comprehensive database that includes this type of peptide as a reference for scholars. ApInAPDB is a database that consists of more than 800 apoptosis-inducing anticancer peptides collected from different articles and it provides comprehensive and useful information about each peptide. The information includes physicochemical properties, secondary structure prediction and descriptors for QSAR modeling among others. Since updating the database with novel information is very important, authors will attempt to update it and add newly studied apoptosis-inducing peptides with their original, physicochemical properties and structural information. Hence, ApInAPDB is certainly helpful for researchers willing to design apoptosis-inducing peptides for cancer therapy.
</p>
    <sec id="Sec14">
      <title>Limitations</title>
      <p id="Par13">In the ApInAPDB database, structural information is not prepared for cyclic peptides and peptides containing modified amino acids due to the lack of online calculation and prediction tools. For D-peptides, only those physicochemical properties are reported which can be calculated with available online tools.</p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>These authors jointly supervised this work: Seyed Shahriar Arab and Ahmad Yari Khosroushahi.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>This is a report of database from Ph.D. thesis registered in Tabriz University of Medical Sciences with the Number 64836. This work was extracted from Naser Faraji's thesis titled “Screening, design and in vitro study of novel anti-breast cancer peptide using bioinformatics algorithms and Nano-modeling” and funded by Grant No. 65618. This research was supported by Research Core: “Bio-Mathematics with computational approach” of Tarbiat Modares University, with Grant No. IG-39706”.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>N.F. cumulated, organized and compiled the data from literature and databases. N.F. extracted and produced the information of peptides. S.S.A. and A.Y.K. conceived the idea and coordinated the project. S.S.A. and A.D. were responsible for development of web interface of the database. N.F. was the writer of the manuscript. N.L.D. was foreign supervisor and collaborator. N.L.D., A.Y.K. and S.S.A. reviewed the manuscript. A.Y.K. and S.S.A. are author responsible for contact and ensures communication.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data availability</title>
    <p>This database is freely available through the following address. (<ext-link ext-link-type="uri" xlink:href="http://bioinf.modares.ac.ir/software/ApInAPDB/">http://bioinf.modares.ac.ir/software/ApInAPDB/</ext-link>).</p>
  </notes>
  <notes id="FPar1" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par14">The authors declare no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Siegel</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Jemal</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Cancer statistics, 2020</article-title>
        <source>CA Cancer J. Clin.</source>
        <year>2020</year>
        <volume>70</volume>
        <fpage>7</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="doi">10.3322/caac.21590</pub-id>
        <pub-id pub-id-type="pmid">31912902</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Marqus</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pirogova</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Piva</surname>
            <given-names>TJ</given-names>
          </name>
        </person-group>
        <article-title>Evaluation of the use of therapeutic peptides for cancer treatment</article-title>
        <source>J. Biomed. Sci.</source>
        <year>2017</year>
        <volume>24</volume>
        <fpage>21</fpage>
        <pub-id pub-id-type="doi">10.1186/s12929-017-0328-x</pub-id>
        <pub-id pub-id-type="pmid">28320393</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>KY</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of subtypes of anticancer peptides based on sequential features and physicochemical properties</article-title>
        <source>Sci. Rep.</source>
        <year>2021</year>
        <volume>11</volume>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="pmid">33414495</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tyagi</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CancerPPD: A database of anticancer peptides and proteins</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>D837</fpage>
        <lpage>D843</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku892</pub-id>
        <pub-id pub-id-type="pmid">25270878</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>XX</given-names>
          </name>
          <name>
            <surname>Eden</surname>
            <given-names>HS</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Peptides in cancer nanomedicine: Drug carriers, targeting ligands and protease substrates</article-title>
        <source>J. Control. Release</source>
        <year>2012</year>
        <volume>159</volume>
        <fpage>2</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jconrel.2011.10.023</pub-id>
        <pub-id pub-id-type="pmid">22056916</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tesauro</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Peptide-based drug-delivery systems in biotechnological applications: Recent advances and perspectives</article-title>
        <source>Molecules</source>
        <year>2019</year>
        <volume>24</volume>
        <fpage>351</fpage>
        <pub-id pub-id-type="doi">10.3390/molecules24020351</pub-id>
        <pub-id pub-id-type="pmid">30669445</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Anti-cancer peptides: Classification, mechanism of action, reconstruction and modification</article-title>
        <source>Open Biol.</source>
        <year>2020</year>
        <volume>10</volume>
        <fpage>200004</fpage>
        <pub-id pub-id-type="doi">10.1098/rsob.200004</pub-id>
        <pub-id pub-id-type="pmid">32692959</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pfeffer</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>ATK</given-names>
          </name>
        </person-group>
        <article-title>Apoptosis: A target for anticancer therapy</article-title>
        <source>Int. J. Mol. Sci.</source>
        <year>2018</year>
        <volume>19</volume>
        <fpage>448</fpage>
        <pub-id pub-id-type="doi">10.3390/ijms19020448</pub-id>
        <pub-id pub-id-type="pmid">29393886</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Baig</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?</article-title>
        <source>Cell Death Dis.</source>
        <year>2016</year>
        <volume>7</volume>
        <fpage>e2058</fpage>
        <lpage>e2058</lpage>
        <pub-id pub-id-type="doi">10.1038/cddis.2015.275</pub-id>
        <pub-id pub-id-type="pmid">26775709</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barras</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Widmann</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Promises of apoptosis-inducing peptides in cancer therapeutics</article-title>
        <source>Curr. Pharm. Biotechnol.</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>1153</fpage>
        <lpage>1165</lpage>
        <pub-id pub-id-type="doi">10.2174/138920111796117337</pub-id>
        <pub-id pub-id-type="pmid">21470140</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Montero</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Letai</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Why do BCL-2 inhibitors work and where should we use them in the clinic?</article-title>
        <source>Cell Death Differ.</source>
        <year>2018</year>
        <volume>25</volume>
        <fpage>56</fpage>
        <lpage>64</lpage>
        <pub-id pub-id-type="doi">10.1038/cdd.2017.183</pub-id>
        <pub-id pub-id-type="pmid">29077093</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kuo</surname>
            <given-names>HM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MSP-4, an antimicrobial peptide, induces apoptosis via activation of extrinsic Fas/FasL-and intrinsic mitochondria-mediated pathways in one osteosarcoma cell line</article-title>
        <source>Mar. Drugs</source>
        <year>2018</year>
        <volume>16</volume>
        <fpage>8</fpage>
        <pub-id pub-id-type="doi">10.3390/md16010008</pub-id>
        <pub-id pub-id-type="pmid">29301308</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Najm</surname>
            <given-names>AAK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Anti-breast cancer synthetic peptides derived from the Anabas testudineus skin mucus fractions</article-title>
        <source>Sci. Rep.</source>
        <year>2021</year>
        <volume>11</volume>
        <fpage>1</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1038/s41598-021-02007-6</pub-id>
        <pub-id pub-id-type="pmid">33414495</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Mahadevappa</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kwok</surname>
            <given-names>HF</given-names>
          </name>
        </person-group>
        <article-title>Venom-based peptide therapy: Insights into anti-cancer mechanism</article-title>
        <source>Oncotarget</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>100908</fpage>
        <lpage>100930</lpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.21740</pub-id>
        <pub-id pub-id-type="pmid">29246030</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gaspar</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Veiga</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Castanho</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>From antimicrobial to anticancer peptides. A review</article-title>
        <source>Front. Microbiol.</source>
        <year>2013</year>
        <volume>4</volume>
        <fpage>294</fpage>
        <pub-id pub-id-type="doi">10.3389/fmicb.2013.00294</pub-id>
        <pub-id pub-id-type="pmid">24101917</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fulda</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Debatin</surname>
            <given-names>KM</given-names>
          </name>
        </person-group>
        <article-title>Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy</article-title>
        <source>Oncogene</source>
        <year>2006</year>
        <volume>25</volume>
        <fpage>4798</fpage>
        <lpage>4811</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.onc.1209608</pub-id>
        <pub-id pub-id-type="pmid">16892092</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kurrikoff</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Aphkhazava</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Langel</surname>
            <given-names>Ü</given-names>
          </name>
        </person-group>
        <article-title>The future of peptides in cancer treatment</article-title>
        <source>Curr. Opin. Pharmacol.</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>27</fpage>
        <lpage>32</lpage>
        <pub-id pub-id-type="doi">10.1016/j.coph.2019.01.008</pub-id>
        <pub-id pub-id-type="pmid">30856511</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fesik</surname>
            <given-names>SW</given-names>
          </name>
        </person-group>
        <article-title>Promoting apoptosis as a strategy for cancer drug discovery</article-title>
        <source>Nat. Rev. Cancer</source>
        <year>2005</year>
        <volume>5</volume>
        <fpage>876</fpage>
        <lpage>885</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc1736</pub-id>
        <pub-id pub-id-type="pmid">16239906</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wong</surname>
            <given-names>RS</given-names>
          </name>
        </person-group>
        <article-title>Apoptosis in cancer: From pathogenesis to treatment</article-title>
        <source>J. Exp. Clin. Cancer Res.</source>
        <year>2011</year>
        <volume>30</volume>
        <fpage>1</fpage>
        <lpage>14</lpage>
        <pub-id pub-id-type="doi">10.1186/1756-9966-30-87</pub-id>
        <pub-id pub-id-type="pmid">21208462</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Peptide-based cancer therapy: Opportunity and challenge</article-title>
        <source>Cancer Lett.</source>
        <year>2014</year>
        <volume>351</volume>
        <fpage>13</fpage>
        <lpage>22</lpage>
        <pub-id pub-id-type="doi">10.1016/j.canlet.2014.05.002</pub-id>
        <pub-id pub-id-type="pmid">24836189</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kapoor</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TumorHoPe: a database of tumor homing peptides</article-title>
        <source>PLoS ONE</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>e35187</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0035187</pub-id>
        <pub-id pub-id-type="pmid">22523575</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>X</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>dbPepNeo: A manually curated database for human tumor neoantigen peptides</article-title>
        <source>Database</source>
        <year>2020</year>
        <volume>2020</volume>
        <fpage>1</fpage>
        <pub-id pub-id-type="doi">10.1093/database/baaa004</pub-id>
        <pub-id pub-id-type="pmid">33002137</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Raghava</surname>
            <given-names>GP</given-names>
          </name>
        </person-group>
        <article-title>ApoCanD: Database of human apoptotic proteins in the context of cancer</article-title>
        <source>Sci. Rep.</source>
        <year>2016</year>
        <volume>6</volume>
        <fpage>1</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="pmid">28442746</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shi</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DRAMP 3.0: an enhanced comprehensive data repository of antimicrobial peptides</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2022</year>
        <volume>50</volume>
        <fpage>D488</fpage>
        <lpage>D496</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkab651</pub-id>
        <pub-id pub-id-type="pmid">34390348</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chiangjong</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Chutipongtanate</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hongeng</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)</article-title>
        <source>Int. J. Oncol.</source>
        <year>2020</year>
        <volume>57</volume>
        <fpage>678</fpage>
        <lpage>696</lpage>
        <pub-id pub-id-type="doi">10.3892/ijo.2020.5099</pub-id>
        <pub-id pub-id-type="pmid">32705178</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dong</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>BioTriangle: a web-accessible platform for generating various molecular representations for chemicals, proteins DNAs/RNAs and their interactions</article-title>
        <source>J. Cheminform.</source>
        <year>2016</year>
        <volume>8</volume>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1186/s13321-016-0146-2</pub-id>
        <pub-id pub-id-type="pmid">26807156</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lamiable</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex</article-title>
        <source>Nucl. Acids Res.</source>
        <year>2016</year>
        <volume>44</volume>
        <fpage>W449</fpage>
        <lpage>W454</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw329</pub-id>
        <pub-id pub-id-type="pmid">27131374</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
